Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:Pf-06840003
go back to main search page
Accession:CHEBI:233415 term browser browse the term
Definition:IDO1 Inhibitor PF-06840003 is an orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor PF-06840003 targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine.
Synonyms:related_synonym: 198474-05-4;   3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione;   Formula=C12H9FN2O2;   InChI=1S/C12H9FN2O2/c13-6-1-2-10-7(3-6)9(5-14-10)8-4-11(16)15-12(8)17/h1-3,5,8,14H,4H2,(H,15,16,17);   InChIKey=MXKLDYKORJEOPR-UHFFFAOYSA-N;   SMILES=O=C1NC(=O)C(C2=CNC=3C=CC(F)=CC32)C1
 xref: CAS:198474-05-4
 xref_mesh: MESH:C000625742


show annotations for term's descendants           Sort by:
Pf-06840003 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions ISO PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of ABCC4 mRNA]
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of ABCC4 mRNA] 		CTD PMID:39172838 NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] promotes the reaction [AHR protein binds to ARNT protein]]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which affects the localization of AHR protein]; PF-06840003 inhibits the reaction [AHR protein binds to ARNT protein] CTD PMID:39172838 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G Ahrr aryl-hydrocarbon receptor repressor multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of AHRR mRNA]
PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of AHRR mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of AHRR mRNA] 		CTD PMID:39172838 NCBI chr 1:28,993,634...29,088,673
Ensembl chr 1:30,810,866...30,952,866 		JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 multiple interactions ISO PF-06840003 inhibits the reaction [APP protein mutant form results in increased expression of ALDH3A1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of ALDH3A1 mRNA] CTD PMID:39172838 NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151 		JBrowse link
G Aldoc aldolase, fructose-bisphosphate C multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of ALDOA mRNA] CTD PMID:39172838 NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,715,489...63,719,133 		JBrowse link
G Angptl4 angiopoietin-like 4 multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of ANGPTL4 mRNA]
PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of ANGPTL4 mRNA] 		CTD PMID:39172838 NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:15,252,473...15,258,681 		JBrowse link
G Ankrd37 ankyrin repeat domain 37 multiple interactions ISO PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of ANKRD37 mRNA] CTD PMID:39172838 NCBI chr16:46,268,933...46,271,971
Ensembl chr16:52,994,740...53,004,545 		JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of APAF1 mRNA]
PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of ABCC4 mRNA]; PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of AHRR mRNA]; PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of CES2A mRNA]; PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of CYP1A1 mRNA]; PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of CYP1B1 mRNA]; PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of CYP2F2 mRNA]; PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of CYP2S1 mRNA]; PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of CYP3A11 mRNA]; PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of CYP51 mRNA]; PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of ERO1L mRNA]; PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of NQO1 mRNA]; PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of UGT1A6A mRNA]; PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of VAV3 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of APAF1 mRNA] 		CTD PMID:39172838 NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:27,381,855...27,466,772 		JBrowse link
G App amyloid beta precursor protein multiple interactions ISO PF-06840003 affects the reaction [APP protein mutant form affects the expression of BACE1 protein]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Adenine]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of alpha-glycerophosphoric acid]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Arginine]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Citric Acid]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Cysteine]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-6-phosphate]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Glucose-6-Phosphate]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Glutamine]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Glyceraldehyde 3-Phosphate]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Histidine]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Isoleucine]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Ketoglutaric Acids]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Lactic Acid]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Lysine]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of malic acid]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of methionine sulfoxide]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Oxaloacetic Acid]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Succinic Acid]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Tryptophan]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Tyrosine]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Uracil]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of ANGPTL4 mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of ANKRD37 mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of ARNT mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of ATR mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of BHLHE40 mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of BLM mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of BNIP3 mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of BNIP3L mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of DDIT4 mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of NAMPT mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of NFKB1 mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of PFKFB3 mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of PFKP mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of PGAM1 mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of SLC2A1 mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of USF2 mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of VDAC1 mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of Adenosine Diphosphate]; PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of Glucose]; PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of Inosine Monophosphate]; PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of Kynurenine]; PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of propionylcarnitine]; PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of Valine]; PF-06840003 inhibits the reaction [APP protein mutant form results in increased expression of ALDH3A1 mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in increased expression of CES2A mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in increased expression of LHB mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in increased expression of SERPINB2 mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in increased expression of SIM1 mRNA]
[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with PF-06840003] results in decreased abundance of Glucose; [APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with PF-06840003] results in decreased abundance of propionylcarnitine; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Acetylglucosamine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Arginine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Choline]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Citric Acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Cysteine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of galactosylhydroxylysine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of gluconic acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glutamic Acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glyceraldehyde 3-Phosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glycine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Histidine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Linoleic Acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of malic acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Methionine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Oleic Acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Ornithine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of palmitoleic acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Pregabalin]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Succinic Acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of tetracosapentaenoic acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Uric Acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Kynurenine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Valine] 		CTD PMID:39172838 NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971 		JBrowse link
G Areg amphiregulin multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of AREG mRNA] CTD PMID:39172838 NCBI chr14:17,256,384...17,265,641
Ensembl chr14:17,256,384...17,265,641 		JBrowse link
G Arnt aryl hydrocarbon receptor nuclear translocator multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] promotes the reaction [AHR protein binds to ARNT protein]]; PF-06840003 inhibits the reaction [AHR protein binds to ARNT protein]
PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of ARNT mRNA] 		CTD PMID:39172838 NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:185,680,683...185,745,546 		JBrowse link
G Atr ATR serine/threonine kinase multiple interactions ISO PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of ATR mRNA] CTD PMID:39172838 NCBI chr 8:105,306,299...105,403,742
Ensembl chr 8:105,306,305...105,403,718 		JBrowse link
G B2m beta-2 microglobulin decreases expression
multiple interactions 		ISO PF-06840003 results in decreased expression of B2M mRNA
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of B2M mRNA] 		CTD PMID:39172838 NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:129,549,318...129,555,356 		JBrowse link
G Bace1 beta-secretase 1 multiple interactions ISO PF-06840003 affects the reaction [APP protein mutant form affects the expression of BACE1 protein] CTD PMID:39172838 NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:55,038,823...55,064,918 		JBrowse link
G Bhlhe40 basic helix-loop-helix family, member e40 multiple interactions ISO PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of BHLHE40 mRNA] CTD PMID:39172838 NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:143,174,048...143,180,783 		JBrowse link
G Blm BLM RecQ like helicase multiple interactions ISO PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of BLM mRNA] CTD PMID:39172838 NCBI chr 1:143,819,072...143,905,300
Ensembl chr 1:143,819,090...143,905,210 		JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions
decreases expression 		ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of BNIP3 mRNA]
PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of BNIP3 mRNA]
PF-06840003 results in decreased expression of BNIP3 mRNA 		CTD PMID:39172838 NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962 		JBrowse link
G Bnip3l BCL2 interacting protein 3 like multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of BNIP3L mRNA]
PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of BNIP3L mRNA] 		CTD PMID:39172838 NCBI chr15:41,174,594...41,197,730
Ensembl chr15:45,334,537...45,373,282 		JBrowse link
G Ces2h carboxylesterase 2H multiple interactions ISO PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of CES2A mRNA]; PF-06840003 inhibits the reaction [APP protein mutant form results in increased expression of CES2A mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CES2A mRNA] CTD PMID:39172838 NCBI chr19:32,974,242...32,988,842
Ensembl chr19:49,884,164...49,898,752 		JBrowse link
G Ctsa cathepsin A decreases expression
multiple interactions 		ISO PF-06840003 results in decreased expression of CTSA mRNA
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of CTSA mRNA] 		CTD PMID:39172838 NCBI chr 3:153,569,106...153,574,983
Ensembl chr 3:173,988,460...173,995,539 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP17A1 mRNA]
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP17A1 mRNA] 		CTD PMID:39172838 NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP1A1 mRNA]
PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of CYP1A1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP1A1 mRNA] 		CTD PMID:39172838 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP1A2 mRNA]
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP1A2 mRNA] 		CTD PMID:39172838 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP1B1 mRNA]
PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of CYP1B1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP1B1 mRNA] 		CTD PMID:39172838 NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142 		JBrowse link
G Cyp2f4 cytochrome P450, family 2, subfamily f, polypeptide 4 multiple interactions ISO PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of CYP2F2 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP2F2 mRNA]
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP2F2 mRNA] 		CTD PMID:39172838 NCBI chr 1:82,416,107...82,429,897
Ensembl chr 1:91,543,768...91,557,553 		JBrowse link
G Cyp2s1 cytochrome P450, family 2, subfamily s, polypeptide 1 multiple interactions ISO PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of CYP2S1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP2S1 mRNA]
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP2S1 mRNA] 		CTD PMID:39172838 NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:90,438,224...90,453,073 		JBrowse link
G Cyp51 cytochrome P450, family 51 multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP51 mRNA]
PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of CYP51 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP51 mRNA] 		CTD PMID:39172838 NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,991,613...31,010,450 		JBrowse link
G Ddit4 DNA-damage-inducible transcript 4 multiple interactions ISO PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of DDIT4 mRNA] CTD PMID:39172838 NCBI chr20:27,891,989...27,894,088
Ensembl chr20:28,434,944...28,437,037 		JBrowse link
G E2f2 E2F transcription factor 2 multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of E2F2 mRNA]
PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of E2F2 mRNA] 		CTD PMID:39172838 NCBI chr 5:153,682,789...153,706,087
Ensembl chr 5:153,682,789...153,706,087 		JBrowse link
G Egln1 egl-9 family hypoxia-inducible factor 1 multiple interactions
decreases expression 		ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of EGLN1 mRNA]
PF-06840003 results in decreased expression of EGLN1 mRNA 		CTD PMID:39172838 NCBI chr19:52,867,900...52,907,308 JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of EIF4EBP1 mRNA] CTD PMID:39172838 NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874 		JBrowse link
G Eno1 enolase 1 increases expression
multiple interactions 		ISO PF-06840003 results in increased expression of ENO1 mRNA
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of ENO1 mRNA]
PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of ENO1 mRNA] 		CTD PMID:39172838 NCBI chr 5:166,002,867...166,014,252
Ensembl chr 3:77,946,261...77,986,003
Ensembl chr 5:77,946,261...77,986,003 		JBrowse link
G Ero1a endoplasmic reticulum oxidoreductase 1 alpha multiple interactions ISO PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of ERO1L mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of ERO1L mRNA] CTD PMID:39172838 NCBI chr15:18,495,037...18,530,440
Ensembl chr15:20,972,679...21,018,039 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of FOS mRNA] CTD PMID:39172838 NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase increases expression
multiple interactions 		ISO PF-06840003 results in increased expression of GAPDH mRNA
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of GAPDH mRNA]
PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of GAPDH mRNA] 		CTD PMID:39172838 NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377 		JBrowse link
G Gpi glucose-6-phosphate isomerase increases expression
multiple interactions 		ISO PF-06840003 results in increased expression of GPI1 mRNA
PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of GPI1 mRNA]
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of GPI1 mRNA] 		CTD PMID:39172838 NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:95,965,396...95,993,261 		JBrowse link
G Gsn gelsolin multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of GSN mRNA] CTD PMID:39172838 NCBI chr 3:38,982,605...39,035,849
Ensembl chr 3:38,982,671...39,035,850 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of GSTA1 mRNA] CTD PMID:39172838 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:31,199,888...31,211,528 		JBrowse link
G Gusb glucuronidase, beta multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of GUSB mRNA] CTD PMID:39172838 NCBI chr12:26,701,188...26,714,718
Ensembl chr12:32,334,075...32,363,024 		JBrowse link
G Gys1 glycogen synthase 1 multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of GYS1 mRNA]
PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of GYS1 mRNA] 		CTD PMID:39172838 NCBI chr 1:95,915,443...95,935,292
Ensembl chr 1:105,051,961...105,072,419 		JBrowse link
G Hk2 hexokinase 2 multiple interactions
increases expression 		ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of HK2 mRNA]
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of HK2 mRNA]
PF-06840003 results in increased expression of HK2 mRNA 		CTD PMID:39172838 NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:116,792,258...116,841,275 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of HMOX1 mRNA] CTD PMID:39172838 NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of HNF4A mRNA] CTD PMID:39172838 NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:172,606,220...172,667,758 		JBrowse link
G Hsp90ab1 heat shock protein 90 alpha family class B member 1 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of HSP90AB1 mRNA] CTD PMID:39172838 NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:22,931,070...22,935,926 		JBrowse link
G Ier3 immediate early response 3 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of IER3 mRNA] CTD PMID:39172838 NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377 		JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of IGFBP3 mRNA] CTD PMID:39172838 NCBI chr14:82,056,347...82,064,083
Ensembl chr14:86,270,208...86,277,944 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of IL6 mRNA]
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of IL6 mRNA] 		CTD PMID:39172838 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Ldha lactate dehydrogenase A multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of LDHA mRNA] CTD PMID:39172838 NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:106,502,182...106,517,521 		JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of LHB mRNA]
PF-06840003 inhibits the reaction [APP protein mutant form results in increased expression of LHB mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of LHB mRNA] 		CTD PMID:39172838 NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:105,037,457...105,038,445 		JBrowse link
G Mapt microtubule-associated protein tau multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] promotes the reaction [AHR protein binds to ARNT protein]]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which affects the localization of AHR protein]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of 3-phosphoglycerate]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Glucose-6-Phosphate]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Glyceraldehyde 3-Phosphate]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Lactic Acid]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Phosphoenolpyruvate]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Pyruvic Acid]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of ALDOA mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of ANGPTL4 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of B2M mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of BNIP3 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of BNIP3L mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of CTSA mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of EGLN1 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of ENO1 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of FOS mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of GAPDH mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of GPI1 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of GYS1 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of HK2 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of MXI1 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of PFKFB3 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of PGAM1 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of PGK1 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of PKM mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of TPI1 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased abundance of Glucose]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased abundance of Kynurenine]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of ABCC4 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of AHRR mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of APAF1 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of AREG mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP17A1 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP1A1 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP1A2 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP1B1 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP2F2 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP2S1 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP3A11 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of CYP51 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of E2F2 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of GSN mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of IL6 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of LHB mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of NFKB1 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of SLC2A3 mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of TIPARP mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of UGT1A6A mRNA]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of VAV3 mRNA]
PF-06840003 affects the reaction [MAPT protein mutant form affects the abundance of Inosine Monophosphate]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Tryptophan]; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased abundance of Kynurenine]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Adenosine Triphosphate]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of alpha-glycerophosphoric acid]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Arginine]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Aspartic Acid]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Citric Acid]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Cysteine]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of fumaric acid]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Glucose-6-Phosphate]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Glyceraldehyde 3-Phosphate]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Ketoglutaric Acids]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Lactic Acid]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Lysine]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of malic acid]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Phenylalanine]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Phosphocreatine]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Phosphoserine]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of propionylcarnitine]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Succinic Acid]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Xanthine]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of EIF4EBP1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of ENO1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of GAPDH mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of GPI1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of GUSB mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of GYS1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of HK2 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of HMOX1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of HNF4A mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of HSP90AB1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of IER3 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of IGFBP3 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of LDHA mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of NAMPT mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of NCOA1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of NDRG1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of NOS3 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PDK1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PER1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PFKFB3 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PFKFB4 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PFKL mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PGAM1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PGF mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PGK1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PIM1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PKM mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of SLC16A3 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of SLC2A1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of SLC2A3 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of TFRC mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of TPI1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of VDAC1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of VEGFA mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased abundance of Adenosine Diphosphate]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased abundance of Glucose]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased abundance of Isoleucine]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased abundance of Kynurenine]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased abundance of threonic acid]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased abundance of Valine]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of AHRR mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of ALDH3A1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of APAF1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CES2A mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP17A1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP1A1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP1A2 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP1B1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP2F2 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP2S1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP3A11 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of CYP51 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of E2F2 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of ERO1L mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of GSTA1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of IL6 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of LHB mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of NQO1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of PTGS2 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of SIM1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of UGT1A6A mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of VAV3 mRNA] 		CTD PMID:39172838 NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108 		JBrowse link
G Mxi1 MAX interactor 1, dimerization protein decreases expression
multiple interactions 		ISO PF-06840003 results in decreased expression of MXI1 mRNA
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of MXI1 mRNA] 		CTD PMID:39172838 NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:262,328,875...262,389,036 		JBrowse link
G Nampt nicotinamide phosphoribosyltransferase multiple interactions ISO PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of NAMPT mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of NAMPT mRNA] CTD PMID:39172838 NCBI chr 6:55,152,756...55,189,547
Ensembl chr 6:55,151,926...55,189,544 		JBrowse link
G Ncoa1 nuclear receptor coactivator 1 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of NCOA1 mRNA] CTD PMID:39172838 NCBI chr 6:32,952,090...33,229,829
Ensembl chr 6:32,952,090...33,195,924 		JBrowse link
G Ndrg1 N-myc downstream regulated 1 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of NDRG1 mRNA] CTD PMID:39172838 NCBI chr 7:100,573,526...100,614,902
Ensembl chr 7:100,573,523...100,614,913 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of NFKB1 mRNA]
PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of NFKB1 mRNA] 		CTD PMID:39172838 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:226,689,745...226,783,088 		JBrowse link
G Nos3 nitric oxide synthase 3 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of NOS3 mRNA] CTD PMID:39172838 NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of NQO1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of NQO1 mRNA] CTD PMID:39172838 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Pdk1 pyruvate dehydrogenase kinase 1 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PDK1 mRNA] CTD PMID:39172838 NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:77,113,473...77,144,145 		JBrowse link
G Per1 period circadian regulator 1 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PER1 mRNA] CTD PMID:39172838 NCBI chr10:53,800,126...53,814,963
Ensembl chr10:54,302,641...54,314,211 		JBrowse link
G Pfkfb3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 decreases expression
multiple interactions 		ISO PF-06840003 results in decreased expression of PFKFB3 mRNA
PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of PFKFB3 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PFKFB3 mRNA]
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of PFKFB3 mRNA] 		CTD PMID:39172838 NCBI chr17:66,983,629...67,064,702
Ensembl chr17:71,893,416...71,975,052 		JBrowse link
G Pfkfb4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PFKFB4 mRNA] CTD PMID:39172838 NCBI chr 8:109,643,558...109,687,006
Ensembl chr 8:118,522,365...118,565,468 		JBrowse link
G Pfkl phosphofructokinase, liver type multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PFKL mRNA] CTD PMID:39172838 NCBI chr20:10,664,285...10,686,324
Ensembl chr20:10,663,955...10,685,966 		JBrowse link
G Pfkp phosphofructokinase, platelet multiple interactions ISO PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of PFKP mRNA] CTD PMID:39172838 NCBI chr17:63,729,743...63,794,026
Ensembl chr17:68,639,481...68,705,752 		JBrowse link
G Pgam1 phosphoglycerate mutase 1 multiple interactions
increases expression 		ISO PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of PGAM1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PGAM1 mRNA]
PF-06840003 results in increased expression of PGAM1 mRNA
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of PGAM1 mRNA] 		CTD PMID:39172838 NCBI chr 1:240,723,832...240,731,443
Ensembl chr 1:250,673,049...250,690,203 		JBrowse link
G Pgf placental growth factor multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PGF mRNA] CTD PMID:39172838 NCBI chr 6:110,547,165...110,557,747
Ensembl chr 6:110,547,153...110,557,747 		JBrowse link
G Pgk1 phosphoglycerate kinase 1 increases expression
multiple interactions 		ISO PF-06840003 results in increased expression of PGK1 mRNA
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of PGK1 mRNA]
PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PGK1 mRNA] 		CTD PMID:39172838 NCBI chr  X:75,336,988...75,352,962
Ensembl chr  X:75,336,687...75,352,959 		JBrowse link
G Pim1 Pim-1 proto-oncogene, serine/threonine kinase multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PIM1 mRNA] CTD PMID:39172838 NCBI chr20:7,556,496...7,560,747
Ensembl chr20:7,556,113...7,561,764 		JBrowse link
G Pkm pyruvate kinase M1/2 multiple interactions
increases expression 		ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of PKM mRNA]
PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of PKM mRNA]
PF-06840003 results in increased expression of PKM mRNA 		CTD PMID:39172838 NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:68,948,815...68,975,396 		JBrowse link
G Psen1 presenilin 1 multiple interactions ISO [APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with PF-06840003] results in decreased abundance of Glucose; [APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with PF-06840003] results in decreased abundance of propionylcarnitine; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Acetylglucosamine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Arginine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Choline]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Citric Acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Cysteine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of galactosylhydroxylysine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of gluconic acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glutamic Acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glyceraldehyde 3-Phosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glycine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Histidine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Linoleic Acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of malic acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Methionine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Oleic Acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Ornithine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of palmitoleic acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Pregabalin]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Succinic Acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of tetracosapentaenoic acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Uric Acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Kynurenine]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Valine] CTD PMID:39172838 NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of PTGS2 mRNA] CTD PMID:39172838 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Serpinb2 serpin family B member 2 multiple interactions ISO PF-06840003 inhibits the reaction [APP protein mutant form results in increased expression of SERPINB2 mRNA] CTD PMID:39172838 NCBI chr13:23,537,312...23,551,823
Ensembl chr13:24,056,021...24,065,031 		JBrowse link
G Sim1 SIM bHLH transcription factor 1 multiple interactions ISO PF-06840003 inhibits the reaction [APP protein mutant form results in increased expression of SIM1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of SIM1 mRNA] CTD PMID:39172838 NCBI chr20:53,827,601...53,907,219
Ensembl chr20:55,410,577...55,489,449 		JBrowse link
G Slc16a3 solute carrier family 16 member 3 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of SLC16A3 mRNA] CTD PMID:39172838 NCBI chr10:106,712,328...106,756,168
Ensembl chr10:106,714,466...106,720,903 		JBrowse link
G Slc2a1 solute carrier family 2 member 1 multiple interactions ISO PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of SLC2A1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of SLC2A1 mRNA] CTD PMID:39172838 NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742 		JBrowse link
G Slc2a3 solute carrier family 2 member 3 multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of SLC2A3 mRNA]
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of SLC2A3 mRNA] 		CTD PMID:39172838 NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:157,632,887...157,646,186 		JBrowse link
G Tfrc transferrin receptor multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of TFRC mRNA] CTD PMID:39172838 NCBI chr11:81,668,478...81,690,318
Ensembl chr11:81,668,478...81,690,318 		JBrowse link
G Tiparp TCDD-inducible poly(ADP-ribose) polymerase multiple interactions ISO PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of TIPARP mRNA] CTD PMID:39172838 NCBI chr 2:152,063,769...152,090,414
Ensembl chr 2:152,063,751...152,090,406 		JBrowse link
G Tpi1 triosephosphate isomerase 1 multiple interactions
increases expression 		ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of TPI1 mRNA]
PF-06840003 results in increased expression of TPI1 mRNA
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased expression of TPI1 mRNA] 		CTD PMID:39172838 NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:159,301,562...159,305,413 		JBrowse link
G Ugt1a6 UDP glucuronosyltransferase family 1 member A6 multiple interactions ISO PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of UGT1A6A mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of UGT1A6A mRNA] CTD PMID:39172838 NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Usf2 upstream transcription factor 2, c-fos interacting multiple interactions ISO PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of USF2 mRNA] CTD PMID:39172838 NCBI chr 1:86,174,703...86,185,942
Ensembl chr 1:95,302,105...95,313,119 		JBrowse link
G Vav3 vav guanine nucleotide exchange factor 3 multiple interactions ISO PF-06840003 inhibits the reaction [APAF1 protein mutant form results in increased expression of VAV3 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased expression of VAV3 mRNA]
PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in increased expression of VAV3 mRNA] 		CTD PMID:39172838 NCBI chr 2:199,699,861...200,042,344
Ensembl chr 2:199,700,445...200,042,343 		JBrowse link
G Vdac1 voltage-dependent anion channel 1 multiple interactions ISO PF-06840003 inhibits the reaction [APP protein mutant form results in decreased expression of VDAC1 mRNA]; PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of VDAC1 mRNA] CTD PMID:39172838 NCBI chr10:36,532,306...36,559,642
Ensembl chr10:37,023,145...37,060,541 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased expression of VEGFA mRNA] CTD PMID:39172838 NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20862
    chemical entity 20860
      atom 20860
        nonmetal atom 20766
          carbon atom 20710
            organic molecular entity 20710
              Pf-06840003 83
Path 2
Term Annotations click to browse term
  CHEBI ontology 20862
    subatomic particle 20860
      composite particle 20860
        hadron 20860
          baryon 20860
            nucleon 20860
              atomic nucleus 20860
                atom 20860
                  main group element atom 20781
                    p-block element atom 20781
                      carbon group element atom 20715
                        carbon atom 20710
                          organic molecular entity 20710
                            Pf-06840003 83
paths to the root